Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
PharmiWeb6d
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...
Pharmabiz5d
Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD
Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...
pharmaphorum1d
FDA changes its mind and approves Takeda’s Eohilia
Takeda had hoped that Eohilia would be the first-ever treatment for EoE, but that crown was snatched by Sanofi and Regeneron’s injectable antibody Dupixent (dupilumab), which was approved for ...
Yahoo Finance3d
Apogee Therapeutics, Inc. (APGE)
DUPIXENT supported by successful completion ... eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, t SAN FRANCISCO and BOSTON, Feb. 25, 2025 ...
pharmaphorum4d
Dupixent nears EU approval for COPD, as FDA delays
Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive ...